Literature DB >> 27791411

Latissimus dorsi myocutaneous reconstruction: a study of long-term outcomes in a district general hospital.

C Kallaway1, A Humphreys1, N Laurence1, R Sutton1.   

Abstract

INTRODUCTION The aim of this study was to evaluate the long-term outcome and durability of both autologous and implant-assisted latissimus dorsi reconstruction in a district general hospital over a 10-year follow-up period. METHODS A prospective cohort study was carried out using a detailed database of all latissimus dorsi flap reconstructions performed by a single consultant surgeon between 2003 and 2013 at the Royal United Hospital, Bath. The long-term outcome following reconstruction was assessed by analysing all episodes of 'reconstruction-specific' operations required from 6 months after the initial surgery. RESULTS The study included 110 patients with latissimus dorsi flap reconstructions, 21 autologous and 95 implant-assisted. Radiotherapy was given to 27 patients with reconstructed flaps. Mean follow-up was 69 months. Further reconstruction-specific surgery was needed in 27 (23%) cases, with 5 of these being post-radiotherapy flaps. Implant-related surgery was the most common reason for further surgery. Complications of the implant itself made up 52% of these cases, chronic sepsis being the most common. The rate of symptomatic capsular contracture requiring further surgery was 4.2%. Of these, one of four patients had undergone radiotherapy. DISCUSSION In our institution, latissimus dorsi reconstruction is durable and safe over the long term, with limited need for further substantial intervention to maintain a good outcome from the initial reconstruction. Autologous flaps were less likely to require further surgery over the long term compared with implant-based reconstructions. The low rate of symptomatic capsular contracture may be due to the protective mechanism provided by the extended harvest flap used.

Entities:  

Keywords:  Breast cancer; Breast implant; Breast reconstruction

Mesh:

Year:  2016        PMID: 27791411      PMCID: PMC5392901          DOI: 10.1308/rcsann.2016.0311

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  8 in total

1.  Latissimus dorsi myocutaneous flap for breast reconstruction.

Authors:  W J Schneider; H L Hill; R G Brown
Journal:  Br J Plast Surg       Date:  1977-10

2.  Early and late capsular "deformation" as a cause of unsatisfactory results in the latissimus dorsi breast reconstruction.

Authors:  J B McCraw; G P Maxwell
Journal:  Clin Plast Surg       Date:  1988-10       Impact factor: 2.017

3.  Breast reconstruction after a radical mastectomy.

Authors:  J Bostwick; L O Vasconez; M J Jurkiewicz
Journal:  Plast Reconstr Surg       Date:  1978-05       Impact factor: 4.730

4.  Autologous latissimus breast reconstruction: a 3-year clinical experience with 100 patients.

Authors:  E Delay; N Gounot; A Bouillot; P Zlatoff; M Rivoire
Journal:  Plast Reconstr Surg       Date:  1998-10       Impact factor: 4.730

5.  Complications of latissimus dorsi myocutaneous flap breast reconstruction.

Authors:  M K Roy; S Shrotia; C Holcombe; D J Webster; L E Hughes; R E Mansel
Journal:  Eur J Surg Oncol       Date:  1998-06       Impact factor: 4.424

6.  Immediate breast reconstruction with latissimus dorsi flap and implant: audit of outcomes and patient satisfaction survey.

Authors:  M R Venus; D J Prinsloo
Journal:  J Plast Reconstr Aesthet Surg       Date:  2008-11-22       Impact factor: 2.740

7.  The timing of autologous latissimus dorsi breast reconstruction and effect of radiotherapy on outcome.

Authors:  D J McKeown; F J Hogg; I M Brown; M J Walker; J R Scott; E M Weiler-Mithoff
Journal:  J Plast Reconstr Aesthet Surg       Date:  2008-02-11       Impact factor: 2.740

8.  Long-term results of breast conservation and immediate volume replacement with myocutaneous latissimus dorsi flap.

Authors:  Fernando Hernanz; Sonia Sánchez; María Pérez Cerdeira; Carlos Redondo Figuero
Journal:  World J Surg Oncol       Date:  2011-12-05       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.